Free Trial
NASDAQ:SRRK

Scholar Rock Q4 2023 Earnings Report

Scholar Rock logo
$32.26 -1.02 (-3.07%)
As of 01:02 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Scholar Rock EPS Results

Actual EPS
-$0.50
Consensus EPS
-$0.49
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Scholar Rock Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Scholar Rock Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Tuesday, March 19, 2024
Conference Call Time
8:00AM ET

Upcoming Earnings

Scholar Rock's Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled at 8:15 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Scholar Rock Earnings Headlines

The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year.tc pixel
See More Scholar Rock Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scholar Rock? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scholar Rock and other key companies, straight to your email.

About Scholar Rock

Scholar Rock (NASDAQ:SRRK), a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

View Scholar Rock Profile

More Earnings Resources from MarketBeat